Rechercher un essai clinique
Autre(s) option(s) de recherche
26 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ESPAGNE
Comunidad Valenciana
VALENCIA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer - ES
Fundación Instituto Valenciano de Oncología (IVO)
Unidad de Investigación Clínica
PAYS-BAS
Noord-Holland
AMSTERDAM
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Medische Oncologie
SUISSE
Suisse Romande
GENÈVE
Nab-PIPAC - A Phase 1b Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity
Hôpitaux Universitaires de Genève HUG
Service d'oncologie
ESPAGNE
Andalucía
CÓRDOBA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Universitario Reina Sofía
Unidad de Oncología Pediátrica
ESPAGNE
Andalucía
CÓRDOBA
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
Hospital Universitario Reina Sofía
Unidad de Oncología Médica y Radioterapia
ESPAGNE
Asturias
OVIEDO
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Universitario Central de Asturias
Servicio de Oncología Médica
ESPAGNE
Cataluña
BARCELONA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Clínic de Barcelona
Servicio de Oncología Médica
ESPAGNE
Cataluña
BARCELONA
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
ESPAGNE
Cataluña
BARCELONA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Oncología Médica y Unidad de curas paliativas
ESPAGNE
Cataluña
GIRONA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
ICO Girona - Hospital Universitario Doctor Josep Trueta
Servicio de Oncología Médica
ESPAGNE
Cataluña
L'HOSPITALET DE LLOBREGAT
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
ESPAGNE
Comunidad Valenciana
VALENCIA
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
Fundación Instituto Valenciano de Oncología
Área Clínica de Oncología Ginecológica
ESPAGNE
Comunidad Valenciana
VALENCIA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Fundación Instituto Valenciano de Oncología (IVO)
Servicio de Oncología Médica
ESPAGNE
Comunidad Valenciana
VALENCIA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Clínico Universitario de Valencia
Servicio de Oncología
ESPAGNE
Comunidad Valenciana
VALENCIA
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
Hospital Clínico Universitario de Valencia
Servicio de Oncología
ESPAGNE
Madrid
MADRID
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Clínico San Carlos
Servicio de Oncología Médica
ESPAGNE
Madrid
MADRID
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
ESPAGNE
Madrid
MADRID
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
Hospital Universitario La Paz
Servicio de Oncología Médica
ESPAGNE
Madrid
MADRID
OSTRIA 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - ES
M.D. Anderson Cancer Center Madrid
Servicio de Oncología Médica
ESPAGNE
Navarra
PAMPLONA
OSTRIA 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - ES
Complejo Hospitalario de Navarra
Servicio de Oncología médica
ITALIE
EMILIA ROMAGNA
BOLOGNA
A randomized, phase III trial of Patupilone vs Pegylated Liposomal Doxorubicin in Taxane in patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer
Policlinico S. Orsola-Malpighi - Area S. Orsola
S.S.D. Oncologia Medica
PAYS-BAS
Gelderland
NIJMEGEN
INTRO study: Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
Radboudumc - Radboud universitair medisch centrum
Laboratorium voor Hematologie
ROYAUME-UNI
Glasgow
GLASGOW
CO-338-017 - A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - UK
Beatson West of Scotland Cancer Centre
ROYAUME-UNI
Greater London
LONDON
SOLO 2: A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
ROYAUME-UNI
Lothian
EDINBURGH
SOLO 1: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy - UK
Western General Hospital
Edinburgh Cancer Research Centre
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS